IL-4 inhibits P-glycoprotein in normal and malignant NK cells.
Patients presenting with a natural killer (NK) cell leukemia generally have a poor prognosis. NK cell tumors are generally resistant to numerous chemotherapeutic drugs and even combination chemotherapy usually results in only short term remissions. The drug resistance of NK cell leukemias may be at least partially explained by their expression of the multidrug resistant transporter, P-glycoprotein (Pgp). In this study, we demonstrate that the expression and function of Pgp activity on NK cells (leukemic and normal) can be reversed with IL-4.
Tambur
A R
AR
Department of Pathology, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL, USA.
Markham
P N
PN
Gebel
H M
HM
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000037:antagonists & inhibitors* / Q000378:metabolism; D002460:Cell Line; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D015847:Interleukin-4 / Q000494:pharmacology*; D007694:Killer Cells, Natural / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D007938:Leukemia / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D011994:Recombinant Proteins
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D011994:Recombinant Proteins; D015847:Interleukin-4